EAM Investors’s Aurinia Pharmaceuticals AUPH Stock Holding History

EAM Investors’s Portfolio AUPH Stock Details AUPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-82,453	Closed	-$904K	–	273
2023 Q1	$904K	Buy	+82,453	New	+$726K	0.18%	236

Other funds holding AUPH

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

EAM Investors's AUPH Position: Q2 2023 in Review

EAM Investors sold out of Aurinia Pharmaceuticals (AUPH) in Q2 2023, closing a stake of 82,453 shares — an estimated $904K sold.

EAM Investors first reported a position in AUPH in Q1 2023 and held it in 1 quarter. The position peaked at $904K in Q1 2023. 200 funds tracked by Wall St. Rank hold AUPH as of Q2 2023.

EAM Investors reported no remaining Aurinia Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
EAM Investors sold 82,453 Aurinia Pharmaceuticals shares in Q2 2023, an estimated $904K.
EAM Investors first reported a position in Aurinia Pharmaceuticals in Q1 2023 and held it in 1 quarter.
EAM Investors's Aurinia Pharmaceuticals position peaked at $904K in Q1 2023.
200 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q2 2023.

Based on EAM Investors's 13F filing for Q2 2023, filed 11 Aug 2023.